Management of Toxicities of BTK Inhibitors in B-Cell Malignancies
Bruton’s tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape of B-cell malignancies. A thorough understanding of the mechanism of action (covalent vs. non-covalent), similarities and differences in their safety profile and management of specific treatment-related adverse events will enable clinicians to use these agents safely and effectively in routine clinical practice.
Category
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation